* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *
Full Coverage

WEX Announces Presentation at Scientific Conference

                   
marketwire.com
Jul 25, 2008
        
Story Timeline:  80 days

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 25, 2008) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that Dr. Neil Hagen, the lead investigator for WEX's Phase III clinical trial of TTX, will make a presentation titled "Tetrodotoxin (TTX): From Poison to Medicine" at the IXth World Conference on Clinical Pharmacology and Therapeutics in Quebec City, Quebec on July 28. For more information, please see www.cpt2008.com. About TTX Tetrodotoxin (TTX), a highly selective sodium channel blocker derived from the puffer fish. Sodium channels are found on nerves and are involved in transmission of nerve impulses. Tetrodotoxin targets a subset of sodium channels found on nerves which conduct pain impulses. There are changes to this subset of sodium channels in chronic pain conditions. Tetrodotoxin is... [read full story]                    

Add Comment
Latest article on this story:

WEX Announces Presentation at Scientific Conference

 redorbit.com Jul 25, 2008
First article on this story:

WEX Announces Presentation at Scientific Conference

 newsblaze.com Jul 25, 2008
Selected publications with coverage of this story:
redorbit.com marketwire.com newsblaze.com
RELATED
Found 2 documents:
                   

WEX Announces Presentation at Scientific Conference

redorbit.com
Jul 25, 2008
        

Posted on: Friday, 25 July 2008, 18:00 CDT VANCOUVER, BRITISH COLUMBIA--(Marketwire - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that Dr. Neil Hagen, the lead investigator for WEX's Phase III...

                   

WEX Announces Presentation at Scientific Conference

newsblaze.com
Jul 25, 2008
        

WEX Pharmaceuticals Inc. announced today that Dr. Neil Hagen, the lead investigator for WEX's Phase III clinical trial of TTX, will make a presentation titled 'Tetrodotoxin : From Poison to Medicine' at the IXth World...